



CATHERINE A. SAZDANOFF

Board member and consultant with extensive experience in global healthcare industry: corporate development strategy and M&A, business development, global expansion and restructuring, legal, compliance and enterprise risk management.

PROFESSIONAL EXPERIENCE:

MERIDIAN BIOSCIENCE, INC. (NASDAQ: VIVO) 2015-present
Independent Director; Chair, Nominating & Governance Committee; member, Compensation Committee; prior member, Audit Committee

- Global diagnostics and life sciences company
- Pending acquisition of Meridian by Korean operating and investment consortium; completed acquisition by Meridian of 3 companies
- Led transition of Board Chair role

VASCUGEN, INC. 2021-present
Independent Director

- Private stem-cell R&D company.

INMED PHARMACEUTICALS, INC. (NASDAQ: INM) 2019-2022
Independent Director; Chair, Nominating & Governance and member, Audit and Compensation Committees

- Developing rare cannabinoid-based Rx treatments for high unmet-need diseases; proprietary bio-synthesis platform.
- Acquisition by InMed of BayMedica Ltd. Including proprietary cannabinoid analogs and IP portfolio.

STRATA ONCOLOGY, INC. 2016-present
Chief Business Development, Compliance and Legal Officer (2021-present)
Previous roles: Strategy/ Business Advisor, Chief Compliance Officer, Chief Business Officer

- Private precision oncology company.

SAZDANOFF CONSULTING LLC 2015 – present
President & CEO

- Healthcare business advisory services, including for: mProve Health (acquired 2017); women's health specialty pharma; Canadian generics company; drug repurposing pharma; novel pain management startup; Neurocern (dementia informatics platform); Vascugen (joined board); Fujifilm Cellular Dynamics Inc.

UNIVERSITY OF CHICAGO 2018-2021

- Lecturer, Business of Biotechnology professional certificate/ graduate credit program.
- Courses: Managing Operations and Board Relations; IP Law.

TAKEDA PHARMACEUTICALS

2006 - 2015

Global corporate roles (VP Global Business Development, VP Corporate Development, VP Head of Corporate Projects, VP Global Licensing, Senior Director BD)

- Built and led corporate M&A team: strategy, target evaluation, banker/ deal source management, all aspects of transactions.
- Lead negotiator/ overall co-lead on acquisition of Nycomed S.A. (US\$ 13.7 B, 2011; >30% increase revenue & EPS, footprint >60 countries), and of Millennium Pharmaceuticals (US\$ 8.8 B, 2008; oncology revenue, pipeline and capabilities).
- Led R&D BD team (CNS, CV/ metabolic, immunology, respiratory, vaccines, GI, renal). Strategy; M&A/ collaboration evaluations and transactions; global integration; partnership governance.
- Led WW restructuring and enterprise risk management initiatives. Exceeded target for US\$ 500 million recurring savings.

ABBOTT LABORATORIES

1984 - 2006

Global corporate and pharmaceutical division roles (Division VP/ Senior Counsel, Office of Ethics & Compliance; Senior Counsel, International Licensing & Acquisitions and Global Litigation; Director, Business Development/ Strategic Licensing; Senior Product Manager)

- Co-lead lawyer on US\$ 7 billion acquisition of Knoll Pharmaceuticals from BASF, adding multiple assets including mega-blockbuster Humira®.
- Lead lawyer and co-lead negotiator on multiple M&A and licensing deals, adding >US\$ 300 MM in revenue, pipeline products and technology rights.
- Increased market share for Biaxin® pediatric antibiotic by 50% in 6 months.
- Led pharmaceutical business development function; closed multiple licensing deals.
- Senior legal advisor for Europe and Canada.
- Roles of increasing responsibility for litigation worldwide (IP, antitrust, contracts, product liability, labor, regulatory, shareholder claims and mass tort litigation); 10-0 trial record.
- Legal advisor to pharmaceutical life cycle management team, extending exclusivity of selected products and adding US \$500 MM additional revenue.
- Successfully resolved infant formula antitrust matters, by trial (civil US \$9 billion claim; Puerto Rico government bid-rigging claim), settlement (FTC) and closure without charges (Canadian Competition Bureau). Favorably settled US federal fraud and abuse investigation in enteral nutrition business, including negotiated Corporate Integrity Agreement.
- Re-launched and globalized compliance program; designed and managed WW operations (~50 staff); directed strategic planning, risk assessments and internal investigations.

ISHAM, LINCOLN & BEALE, Chicago IL
Litigation associate.

1981 - 1983

EDUCATION:

J.D., Northwestern University School of Law

B.A. (English with honors), University of Notre Dame

PROFESSIONAL AFFILIATIONS (current): NACD; DirectWomen; Women Corporate Directors; Mentor-in-Residence at MATTER Chicago; Executive-in-Residence and External Advisory Board member for Rosalind Franklin University Innovation and Research Park; Cristo Rey St. Martin College Prep School Jobs Committee; Practicing Law Institute Advanced Licensing course faculty.